LL-III/11

General Information


DRACP ID  DRACP00372

Peptide Name   LL-III/11

Sequence  VNWKKIILGKIIKVVK

Sequence Length  16

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Membrane-targeted



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma IC50=8±1 µM MTT assay 48 h 1
SW480 Colon adenocarcinoma Carcinoma IC50=48 µM MTT assay 48 h 1
CCRF-CEM Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia Leukemia IC50=4±1 µM MTT assay 48 h 1

Hemolytic Activity  Rat erythrocytes: IC50>200 μM

Normal (non-cancerous) Cytotoxicity  HUVEC: IC50=50± μM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antimicrobial; Antifungal



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00372

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C92H163N23O18

Absent amino acids  ACDEFHMPQRSTY

Common amino acids  K

Mass  214720

Pl  11.4

Basic residues  5

Acidic residues  0

Hydrophobic residues  9

Net charge  5

Boman Index  560

Hydrophobicity  63.13

Aliphatic Index  176.25

Half Life 
  Mammalian: 100 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  5500

Absorbance 280nm  366.67

Polar residues  2

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 22100226

Title  Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells

Doi 10.1016/j.peptides.2011.11.002

Year  2012

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.